Sam Chun Dang Pharm Co Ltd

Sam Chun Dang Pharm Co Ltd has a highly leveraged capital structure, with a price-to-book ratio of 32.69 and a debt-to-equity ratio of 0.25, indicating a relatively low debt burden compared to equity. However, the company's liquidity position is constrained, as evidenced by a negative net cash position after subtracting total debt. The current ratio of 2.27 suggests the company can cover its short-term liabilities, but the free cash flow of -41,224,795,220 KRW indicates a significant outflow of cash, primarily driven by capital expenditures of -59,588,372,440 KRW. Profitability metrics are weak, with a return on equity (ROE) of 1.91% and a return on assets (ROA) of 0.94%, both significantly below the industry median for pharmaceutical companies. The company's net income of 5,261,822,740 KRW is modest relative to its revenue of 231,805,277,740 KRW, resulting in a net margin of approximately 2.27%. This suggests that the company is not efficiently converting revenue into profit, which could be a concern for investors. Geographically and segment-wise, the company's exposure is not disclosed in the available data, but the lack of segmental or geographic breakdown in the financials implies a concentration risk. The absence of detailed segment reporting makes it difficult to assess the company's diversification and exposure to different markets or product lines. The company's growth trajectory is uncertain, as the most recent actual revenue of 166,862,000,000 KRW is lower than the reported revenue of 231,805,277,740 KRW, suggesting a potential decline in performance. Analysts have not provided forward-looking revenue estimates, and the company's earnings per share (EPS) were negative at -45.00 KRW, indicating a loss in the most recent reporting period. Risk factors include a medium liquidity risk due to the negative net cash position and a high price-to-earnings ratio of 1,715.01, which suggests the stock is overvalued relative to earnings. The company also faces a potential dilution risk, although it is currently rated as low. The valuation is further inflated by an enterprise value to EBITDA ratio of 1,079.35, which is extremely high and may not be sustainable. Recent events include the disclosure of a negative EPS and a decline in revenue, which may signal underlying operational challenges. The company has not issued any recent press releases or filed notable regulatory updates, but the financial data suggests a need for closer monitoring of its liquidity and profitability trends.